InsiderTrades.com logo
Unveiled: NVIDIA’s "Secret Royalty" Program
From Behind the Markets   |   Ad
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Click Here to learn how to get in now >>>

SKYE Insider Trading

Insider Ownership Percentage: 0.73%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,750,352.22

Skye Bioscience Insider Trading History Chart

This chart shows the insider buying and selling history at Skye Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Skye Bioscience Share Price & Price History

Current Price: $5.67
Price Change: ▲ Price Increase of +0.43 (8.21%)
As of 09/19/2024 12:29 PM ET

This chart shows the closing price history over time for SKYE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company   |   Ad
The AI boom is just getting started. And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.

Skye Bioscience Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2024Andrew J SchwabDirectorSell13,837$6.06$83,852.2266,277View SEC Filing Icon  
9/11/2024Andrew J SchwabDirectorSell252,500$6.60$1,666,500.0066,356View SEC Filing Icon  
See Full Table
Unveiled: NVIDIA’s "Secret Royalty" Program
From Behind the Markets   |   Ad
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Click Here to learn how to get in now >>>

SEC Filings (Institutional Ownership Changes) for Skye Bioscience (NASDAQ:SKYE)

21.09% of Skye Bioscience stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SKYE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Skye Bioscience Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
9/16/2024Point72 DIFC Ltd6,000$48K0.0%N/A0.021%Search for SEC Filing on Google Icon
9/16/2024Cubist Systematic Strategies LLC3,762$30K0.0%N/A0.013%Search for SEC Filing on Google Icon
9/16/2024Point72 Asia Singapore Pte. Ltd.27,768$0.22M0.0%N/A0.099%Search for SEC Filing on Google Icon
8/19/2024Point72 Asset Management L.P.560,000$4.49M0.0%N/A1.995%Search for SEC Filing on Google Icon
8/16/2024Perceptive Advisors LLC500,000$4.01M0.1%N/A1.781%Search for SEC Filing on Google Icon
8/16/2024Driehaus Capital Management LLC650,758$5.21M0.0%N/A2.319%Search for SEC Filing on Google Icon
8/15/2024CVI Holdings LLC679,739$5.45M4.9%N/A2.422%Search for SEC Filing on Google Icon
8/15/2024Point72 Asia Singapore Pte. Ltd.27,768$0.22M0.0%N/A0.099%Search for SEC Filing on Google Icon
8/14/2024Cubist Systematic Strategies LLC3,762$30K0.0%N/A0.013%Search for SEC Filing on Google Icon
8/14/2024Point72 DIFC Ltd6,000$48K0.0%N/A0.021%Search for SEC Filing on Google Icon
8/14/2024Logos Global Management LP1,301,518$10.43M0.8%N/A4.637%Search for SEC Filing on Google Icon
8/8/2024AdvisorShares Investments LLC26,000$0.21M0.0%N/A0.093%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers19,754$0.16M0.0%N/A0.070%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp58,778$0.47M0.0%N/A0.209%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Skye Bioscience logo
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Read More on Skye Bioscience

Today's Range

Now: $5.67
Low: $5.35
High: $5.89

50 Day Range

MA: $5.85
Low: $4.66
High: $6.99

52 Week Range

Now: $5.67
Low: $1.44
High: $19.41

Volume

38,835 shs

Average Volume

125,121 shs

Market Capitalization

$159.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Who are the company insiders with the largest holdings of Skye Bioscience?

Skye Bioscience's top insider shareholders include:
  1. Andrew J Schwab (Director)
Learn More about top insider investors at Skye Bioscience.

Who are the major institutional investors of Skye Bioscience?

Skye Bioscience's top institutional investors include:
  1. Logos Global Management LP — 4.64%
  2. CVI Holdings LLC — 2.42%
  3. Driehaus Capital Management LLC — 2.32%
  4. Point72 Asset Management L.P. — 2.00%
  5. Perceptive Advisors LLC — 1.78%
  6. Bank of New York Mellon Corp — 0.21%
Learn More about top institutional investors of Skye Bioscience stock.

Which institutional investors are buying Skye Bioscience stock?

In the last quarter, SKYE stock was acquired by institutional investors including:
  1. Logos Global Management LP
  2. CVI Holdings LLC
  3. Driehaus Capital Management LLC
  4. Point72 Asset Management L.P.
  5. Perceptive Advisors LLC
  6. Bank of New York Mellon Corp
  7. Point72 Asia Singapore Pte. Ltd.
  8. Point72 Asia Singapore Pte. Ltd.
Unveiled: NVIDIA’s "Secret Royalty" Program
From Behind the Markets   |   Ad
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Click Here to learn how to get in now >>>